benefitted for so many years of stable funding from the NIHR .
“ In response to this situation , Cochrane has decided to disband … but we ’ d like to be clear that the reasons for the NIHR ’ s decision have nothing to do with CTAG individually , or any of our work .” The spokesperson added that the group is ‘ optimistic ’ about securing alternative funding , saying that the CTAG ‘ will continue its research ’… just not as a part of Cochrane . Following the announcement , Vapouround Editor Patrick Griffin said : “ I was deeply saddened to learn that the CTAG will soon
I fail to see how the benefits of a stable presence , extraordinary accrued expertise and knowledge can be replaced … Cochrane Review Groups should be cherished . be phased out … this is truly the end of an era .
“ I would like to thank the group for its continued diligence , its pursuit of the evidence and all that it has done for global tobacco harm reduction efforts .
He hoped that the CTAG ’ s crucial work could continue long after the 2023 deadline , saying that the loss of this ‘ pragmatic ’ and ‘ respected ’ review body would ‘ no doubt leave a void in tobacco research ’.
The NIHR was unavailable for comment .
VM37 l 43